Rebecca A. Shatsky

Jul 16, 2024 | ascopubs.org | Rebecca A. Shatsky |Ana C. Garrido-Castro |William Gradishar

NAT for EBC provides multiple advantages. Historically, NAT was only given for inoperable or locally advanced BC with the goal of downstaging tumors in the breast and axilla to render them operable and/or more likely to achieve breast conservation.

Jun 7, 2024 | hmpgloballearningnetwork.com | Rebecca A. Shatsky

Rebecca Shatsky, MD, University of California, San Diego, La Jolla, California, discusses results from the multicenter, phase 2 I-SPY2.2 trial, a platform sequential multiple assignment randomized trial (SMART), evaluating novel experimental neoadjuvant regimens for breast cancer. These results show pCR rates of patients who received datopotamab deruxtecan plus durvalumab.

Jun 3, 2024 | targetedonc.com | Rebecca A. Shatsky

The ISPY2.2 trial (NCT01042379) presented as a late-breaking abstract at the 2024 ASCO Annual Meeting explores a new approach to treating high-risk breast cancer in the neoadjuvant setting. It uses a platform design to test multiple treatment combinations efficiently. Patients are classified into 6 tumor response predictive subtypes (RPS) based on factors like immune response, DNA repair, and hormone receptor status.

Mar 29, 2024 | targetedonc.com | Rebecca A. Shatsky

2 Commerce Drive Cranbury, NJ 08512

Mar 7, 2024 | targetedonc.com | Rebecca A. Shatsky

Rebecca A. Shatsky, MD, associate professor of medicine at UC San Diego School of Medicine, discusses the benefits of a subcutaneous (SC) injection of pertuzumab (Perjeta), trastuzumab (Herceptin), and hyaluronidase-zzfx (Phesgo) compared with intravenous (IV) trastuzumab and pertuzumab for patients with HER2-positive breast cancer.